ABOUT 22nd_BEF
> REGISTRATION​​​
​> SPONSORS
> SUPPORTERS​​​​
> NETWORKING​​​

> ABOUT LAST YEAR​​​

SILVER SPONSORs

BEIGENE ltd.

BeiGene is a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide. With a broad portfolio of more than 40 clinical candidates, we are expediting development of our diverse pipeline of novel therapeutics through our own capabilities and collaborations. We are committed to radically improving access to medicines for two billion more people by 2030. BeiGene has a growing global team of over 8,000 colleagues across five continents. 

www.beigene.com/

EIT HEALTH E.V.

EIT Health is a network of best-in-class health innovators backed by the EU. We deliver solutions to enable European citizens to live longer, healthier lives by promoting innovation. We connect the right people and the right topics across European borders, so that innovation can happen at the intersection of research, education and business.

https://www.eithealth.eu/web/internet-eithealth​

lifesci PARTNERS

With global presences in New York, Boston, San Francisco / Silicon Valley, Chicago, Charlotte, London, Zurich, Paris, Milan, and Tel-Aviv, LifeSci Partners leverages its relationships and knowledge in multiple territories around the world to provide high value services in investor relations & corporate access, communications, BD&L & strategic consulting, search, expert network access, venture, equity research & banking.

​​lifescipartners.com/

TORREYA

A global investment banking boutique serving companies in the life sciences industry. Since our inception in 2007, we have advised clients on more than $100 billion worth of deals for biotechnology, branded pharmaceutical, generic pharmaceutical, and life sciences companies.  Our partners are senior industry bankers and executives, with deep experience, knowledge, and networks. We are a partner of choice for companies seeking discreet, conflict-free, and knowledgeable advice on M&A, pharmaceutical asset sale, capital markets, and licensing transactions.  Torreya is differentiated from most other life sciences advisory practices by the breadth of its global presence. Over half the transactions on which we advise are cross-border.  Torreya has offices in London, Mumbai, and New York, and affiliate offices on six continents.

https://torreya.com/

---

Bronze sponsor

Merck KGaA, Darmstadt, Germany

We are Merck KGaA, Darmstadt, Germany, a vibrant science and technology company.

Science is at the heart of everything we do. It drives the discoveries we make and the technologies we create.

The passion of our curious minds makes a positive difference to millions of people’s lives every day.

In Healthcare, we discover unique ways to treat the most challenging diseases, such as multiple sclerosis and cancer. Our Life Science experts empower scientists by developing tools and solutions that help deliver breakthroughs more quickly. And in Electronics, we develop science that sits inside technologies and changes the way we access, store, process, and display information.

Everything we do is fueled by a belief in science and technology as a force for good. A belief that has driven our work since 1668 and will continue to inspire us to find more joyful and sustainable ways to live.

We are curious minds dedicated to human progress.

​www.merckgroup.com/en/company/partnering/collaboration/collaboration-in-healthcare/strategic-focus-and-partnerships.html

---

CONTRIBUTING SPONSOR

Marker Therapeutics, Inc.

Marker Therapeutics (Marker) is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and innovative peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. Marker developed lead product candidates from MultiTAA-specific T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets.

www.markertherapeutics.com/

NOVO HOLDINGS A/S

Novo Ventures is a global team of investment professionals employed by Novo affiliates that supports Novo Holdings’ investments in private, public and structured product opportunities in the life sciences industry. Novo Holdings A/S is a private limited liability company wholly owned by the Novo Nordisk Foundation. It is the holding and investment company of the Novo Group, comprising Novo Nordisk A/S and Novozymes A/S, and is responsible for managing the Foundation’s assets. Novo Holdings is recognized as a world-leading life science investor with a focus on creating long-term value. As a life science investor, Novo Holdings provides seed and venture capital to development-stage companies and takes significant ownership positions in growth and well-established companies. Novo Holdings also manages a broad portfolio of diversified financial assets. 

https://www.novoholdings.dk/

PharmaVentures Ltd.

PharmaVentures is a premier transaction advisory firm and a leading international company in partnering, M&A deals and strategic alliances. For the past 28 years, PharmaVentures has acted as advisor on over 900 deal related projects covering licensing, mergers, acquisitions, divestments, and joint venture activities for companies worldwide.

PharmaVentures’ deep bank of specialist experience, deal analytics and network of contacts from innovators to large pharma makes us uniquely placed to support business in all aspects of deal making and strategic planning. PharmaVentures is well known for its deep insight into deal structures and its success for generating partnering interest.

PharmaVentures’ services include:
•    M&A (divestments, mergers, acquisitions, and strategic transactions)
•    Licensing (in and out licensing)
•    Fundraising
•    Strategy (commercialisation, deal strategy, due diligence, market entry)
•    Valuation and Positioning (licensing, M&A, fundraising, and expert testimonies)

PharmaVentures is based in Oxford, UK, and employs over 20 professionals and has associates in Asia-Pacific.
PharmaVentures Capital Ltd is a wholly owned subsidiary of PharmaVentures Ltd. All regulated activities are delivered through PharmaVentures Capital Ltd, which is authorised and regulated by the Financial Conduct Authority (741356).

www.pharmaventures.com/